Compare Msci Inc (MSCI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs TG Therapeutics Inc — how do they compare? Msci Inc trades at $560.34 (market cap $40.84B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Msci Inc is far larger — about 5.3× TG Therapeutics Inc's market cap, and Msci Inc pays a 1.46% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MSCI | TGTX | |
|---|---|---|
Market Cap | $40.84B | $7.64B |
Sector | Financials | Health |
52-Week High | $643.83 | $59.06 |
52-Week Low | $511.84 | $26.94 |
Enterprise Value | $47.00B | $7.84B |
Dividend Yield | 1.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $563.01, down slightly (-0.01%) with a bearish technical signal. The company maintains strong fundamentals with $3.13B revenue, 40.73% net margin, and consistent earnings beats in three of the last four quarters. Recent acquisitions and strategic partnerships enhance its private markets platform. Analyst consensus remains strongly bullish with a $728.14 price target, representing 29% upside potential from current levels.
The outlook remains positive given MSCI's recurring revenue model, high client retention, and secular growth in private markets. Key risks include execution of recent acquisitions and market sensitivity to index performance. With strong profitability and Wall Street support, the stock presents a compelling long-term opportunity despite near-term technical weakness.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
